Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
On November 1, 2018, the Centers for Medicare & Medicaid Services (CMS) finalized its rule for the 2019 Physician Fee Schedule (PFS) and the Quality Payment Program (QPP).
On October 30, 2018, the Centers for Medicare and Medicaid Services (CMS) published an Advanced Notice of Proposed Rulemaking (ANPRM) for a potential International Pricing Index (IPI) Model for Medicare Part B Drugs.
On October 18, 2018, the Centers for Medicare & Medicaid Services (CMS) issued a new proposed rule entitled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Facilitating Competition and Innovation in the Biological Products Marketplace; Public Hearing; Request for Comments” as published in the Federal Register on July 25, 2018.
The Academy of Managed Care Pharmacy (AMCP) thanks Congress for its dedication to combatting the opioid epidemic. The importance of H.R. 6 increases as the number of preliminary CDC reported overdose deaths rise (72,000 overdose deaths in 2017). Both pieces of legislation passed by the House and Senate will advance patient treatment and recovery initiatives, improve prevention of opioid addiction, protect communities, and increase education initiatives for patients and providers.
AMCP supports the concept of collaborative drug therapy management (CDTM), a formal partnership between a pharmacist and a prescriber that allows the pharmacist to manage a patient’s drug therapy. CDTM, also referred to as collaborative practice, allows pharmacists to use their unique skills and abilities to complement other types of care provided by collaborating professionals to optimize patient outcomes.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide comments in response to the Centers for Medicare and Medicaid Services’ (CMS’) proposed Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2019; Medicare Shared Savings Program Requirements; Quality Payment Program; and Medicaid Promoting Interoperability Program (CMS-1693-P).
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Patient-Focused Drug Development on Chronic Pain; Public Meeting; Request for Comments” as published in the Federal Register on July 11, 2018.
The Academy of Managed Care Pharmacy (AMCP) supports off‐label use of FDA‐approved drugs when medically appropriate and necessary, but opposes government‐mandated coverage of specific pharmaceuticals, whether for FDA‐approved or off‐label uses.
The Academy of Managed Care Pharmacy (AMCP) is writing in strong support of the “Opioid Crisis Response Act”. The importance of this Act increases as the number of overdose deaths according to the CDC rise (72,000 overdose deaths in 2017).1 As you know, the Act will advance patient treatment and recovery initiatives, improve prevention of opioid addiction, protect communities, and bolster efforts to fight deadly illicit synthetic drugs like fentanyl.
The Academy of Managed Care Pharmacy (AMCP) is writing in strong support of the “Opioid Crisis Response Act”. The importance of this Act increases as the number of overdose deaths according to the CDC rise (72,000 overdose deaths in 2017).
The Academy of Managed Care Pharmacy (AMCP) writes in strong support of requiring electronic transmission of prescriptions (e-Rx) as proposed in Assembly Bill 2789. AMCP believes that the electronic exchange of prescription, drug benefit, and drug information improves patient drug therapy, increases operational efficiencies and optimizes health care outcomes and will decrease abuse and diversion of prescriptions for controlled substances.
